Table 1.
Cell line | BRT | BRH | BRD | BRE | BRR | BDT | BDH | BDD | BDE | doxorubicin |
---|---|---|---|---|---|---|---|---|---|---|
HepG2 | 1.28 | −2.078 | −8.02 | −8.43 | −13.74 | 1.66 | −7.43 | −16.18 | −6.62 | 91.28 ± 0.3 |
MDA-MB-231 | −15.86 | − 9.70 | −18.83 | −25.52 | − 23.30 | − 6.19 | − 6.73 | 13.17 | −20.64 | 97.69 ± 0.4 |
A549 | 0.44 | −0.81 | 7.85 | −8.37 | −0.89 | 12.59 | 8.18 | 14.99 | −6.52 | 98.05 ± 0.0 |
Results are presented as growth inhibition percentage at concentration of 20 μg/mL, mean (n = 1). Doxorubicin (2 μg/mL) was used as the reference drug, mean ± SD (n = 2). BRT: B. rupestris total methanol extract; BHT: B. rupestris n-hexane fraction; BRD: B. rupestris dichloromethane fraction; BRE: B. rupestris ethyl acetate fraction; BRR: B. rupestris remaining MeOH(aq) fraction; BDT: B. discolor total methanol extract; BDH: B. discolor n-hexane fraction; BDD: B. discolor dichloromethane fraction; BDE: B. discolor ethyl acetate fraction